Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia

Dekker, Simone E.; Rea, Delphine; Cayuela, Jean-Michel; Arnhardt, Isabell; Leonard, Jessica; Heuser, Michael

doi:10.1200/edbk_390010

Cited by 16 publications

(8 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we confirmed similar efficacy in detecting MRD positivity for both flow cytometry and real‐time PCR, as previously described. 22 , 23 …”

Section: Discussionmentioning

confidence: 99%

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Serio,

Grimaldi,

Ammirati

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundGemtuzumab‐ozogamycin (GO) is approved in combination with high‐dose chemotherapy for treatment‐naïve low‐ and intermediate‐risk acute myeloid leukemia (AML).AimsIn this retrospective real‐life multicenter study, we reported efficacy and safety of GO plus high‐dose chemotherapy in newly diagnosed AML patients.Methods and ResultsA total of 31 fit low‐ and intermediate‐risk AML patients treated with GO‐based regimens were retrospectively included in this real‐life multicenter study, and results were compared with a control cohort treated with 3 + 7 alone. Complete remission (CR) rate after induction was 77%, and most responders (45%) underwent two GO‐based consolidation, and minimal residual disease (MRD) negativity was observed in 17 cases (55%) after the end of consolidation. Low genetic risk was associated with increased CR rate compared with intermediate‐risk AML (88% vs. 33%; p < .001), as well as prolonged overall survival (OS; hazard ratio, 0.16; 95% confidential interval, 0.02–0.89; p < .001). GO addition resulted in a survival benefit for low‐risk AML (median OS not reached vs. 25 months; p = .19) while not for intermediate‐risk subjects (10 vs. 13 months; p = .92), compared with the control group. Moreover, GO‐treated patients experienced fever of unknown origin or sepsis in 42% or 36% of cases, respectively, with one death during induction due to septic shock, with similar rates compared with the control group (p = .3480 and p = .5297, respectively). No cases of veno‐occlusive disease after allogeneic transplantation were observed.ConclusionsOur real‐life multicenter study confirmed GO‐based treatment efficacy with high MRD negativity rates in fit newly diagnosed AML patients, especially in those with low genetic risk and core binding factor, while limited benefits were observed in intermediate‐risk AML. However, further validation on larger prospective cohorts is required.

show abstract

“…However, we confirmed similar efficacy in detecting MRD positivity for both flow cytometry and real‐time PCR, as previously described. 22 , 23 …”

Section: Discussionmentioning

confidence: 99%

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Serio,

Grimaldi,

Ammirati

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

show abstract

“…The assessment of MRD in chronic hematological disorders (chronic myeloid leukemia [4] and multiple myeloma [5]) as well as in acute conditions such as acute lymphoblastic leukemia [6,7] or AML is a crucial aspect enabling disease monitoring. Presently, it is widely accepted that MRD serves as a powerful and independent predictive and prognostic tool.…”

Section: Mrd Definitionmentioning

confidence: 99%

“…Presently, it is widely accepted that MRD serves as a powerful and independent predictive and prognostic tool. It facilitates both the early evaluation of patients' remission status and the likelihood of relapse, aiding in therapeutic decision-making, and serves as a biomarker of efficacy in clinical trials [4,[8][9][10][11][12][13][14][15].…”

Section: Mrd Definitionmentioning

confidence: 99%

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

Chea,

Rigolot,

Canali

et al. 2024

IJMS

View full text Add to dashboard Cite

Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.

show abstract

“…As in other hematological malignancies, such as chronic myeloid (CML) and acute lymphoblastic leukemia (ALL), MRD evaluation in AML serves various purposes: to offer a quantitative approach for determining the depth of remission, to enhance the assessment of relapse risk after achieving remission, and to detect signs of an impending relapse earlier allowing for immediate intervention [ 5 , 9 ]. Furthermore, MRD negativity represents a potential surrogate endpoint for clinical trials in predicting survival [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

Moritz,

Schwab,

Reinisch

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is an aggressive malignant disease with a high relapse rate due to the persistence of chemoresistant cells. To some extent, these residual cells can be traced by sensitive flow cytometry and molecular methods resulting in the establishment of measurable residual disease (MRD). The detection of MRD after therapy represents a significant prognostic factor for predicting patients’ individual risk of relapse. However, due to the heterogeneity of the disease, a single sensitive method for MRD detection applicable to all AML patients is lacking. This review will highlight the advantages and limitations of the currently available detection methods—PCR, multiparameter flow cytometry, and next generation sequencing—and will discuss emerging clinical implications of MRD test results in tailoring treatment of AML patients.

show abstract

Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia

Cited by 16 publications

References 66 publications

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

Contact Info

Product

Resources

About